13 11 20

Information and support

  • Get informed
  • Get support
  • Cut my risk
  • Get involved
  • Research
  • Gilead

    Acronym: 

    Gilead

    ACTRN/NCT /ethics: 

    NCT02536300

    Scientific title: 

    Dose optimization of idelalisib in follicular lymphoma

    Summary of trial and patient characteristics

    Cancer Type Lymphoma
    Trial Type Treatment
    Phase All phases Tumour Stream Lymphoma
    Age Range 18 years and older Cancer Stage
    Sex Both Anticipated Start Date 2016-11-01
    Molecular Target Anticipated End Date
    Cancer Type Lymphoma
    Trial Type Treatment
    Phase All phases
    Age Range 18 years and older
    Sex Both
    Molecular Target
    Tumour Stream Lymphoma
    Cancer Stage
    Anticipated Start Date 2016-11-01
    Anticipated End Date

    Trial Summary

    The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.

    Lay Summary

    Dose optimization of idelalisib in follicular lymphoma

    Sponsor / Cooperative group

    Gilead Sciences

    Participating Hospitals

    Hospital Clinical Trial Coordinator Email Phone Principal Investigator Recruitment Status
    Calvary North Adelaide Hospital Julie Rowe julie.rowe@calvarycare.org.au 08 8239 9536 Dr Wilfrid Jaksic Recruiting